Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Clinical Trial for the Treatment of Lateral Epicondylitis with Debridement Arthroscopic Versus Cytokine-Rich Autologous Serum (SARC)
2024-515941-40-00Phase 4Authorised
- Sponsor
- Hospital Universitari Parc Taulí
- Start
- Nov 2024
- Countries
- 1
01
Overview
Phase 4, randomised trial of autologous cytokine-rich serum in Lateral Epicondylitis (LET) (2 arms), sponsored by Hospital Universitari Parc Taulí. Primary endpoints: Treatment completion of SARC injections and Pain reduction and functional improvement (medium term). Planned start Nov 2024; status: authorised.
02
Drugs
autologous cytokine-rich serum
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on 2024-515941-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515941-40-00.